Lack Of Catalysts Keeps Analysts Away From Pfizer
Pfizer (PFE) may not be the best investment in coming months, as analysts say the company's near-term prospects are uninspiring. Despite leading drug brands, including a treatment for metastatic breast cancer called Ibrance and a pneumonia vaccine known as Prevnar-13, these analysts say the company needs to do more to jump-start growth.
"We see few major catalysts that can drive outperformance for the shares as well as slowing momentum for Ibrance and potentially a slow decline going forwards for Prevnar-13," analyst Jeffrey Holford of Jefferies LLC wrote in a note.
"We see few major catalysts that can drive outperformance for the shares as well as slowing momentum for Ibrance and potentially a slow decline going forwards for Prevnar-13," analyst Jeffrey Holford of Jefferies LLC wrote in a note.